Disclosed herein are systems, compositions, and methods for modifying the human dystrophin gene (DMD). Systems, compositions, and methods may comprise a compact Type V CRISPR-associated (Cas) protein, an RNA-dependent DNA polymerase, and/or one or more guide nucleic acids or uses thereof. These systems, compositions, and methods may be useful for treating diseases such as Duchenne muscular dystrophy (DMD).

This invention relates to recombinant nucleic acid constructs encoding Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas systems and transposon 7-like (Tn7-like) transposon systems for DNA integration, as well as methods of using the same.